In the remaining cases, information on CDKN2A/B status was missing in 40 patients with IDH-mutant astrocytoma, and information on molecular features of glioblastoma (TERT mutation, EGFR amplification, 7p + /10q-) was missing in 27 patients with IDH-wildtype glioma. This evidence concerns the gene EGFR and central nervous system cancer.